scholarly journals Temporal Relationship Between Visual Field, Retinal and Microvascular Pathology Following 125I-Plaque Brachytherapy for Uveal Melanoma

2021 ◽  
Vol 62 (1) ◽  
pp. 3
Author(s):  
Michelle R. Tamplin ◽  
Wenxiang Deng ◽  
Mona K. Garvin ◽  
Elaine M. Binkley ◽  
Daniel E. Hyer ◽  
...  
2021 ◽  
Author(s):  
Shiva Sabazade ◽  
Viktor Torgny Gill ◽  
Christina Herrspiegel ◽  
Gustav Stålhammar

Abstract PurposeFluid-conducting extracellular matrix patterns known as vasculogenic mimicry (VM) have been associated with poor prognosis in uveal melanoma and other cancers. We investigate the correlations between VM, presenting symptoms, mortality and the area density of periodic acid-Schiff positive histological patterns (PAS density).MethodsSixty-nine patients that underwent enucleation for uveal melanoma between 2000 and 2007 were included. Clinicopathological parameters, presenting symptoms and outcomes were collected. Histological tumor sections were evaluated for VM and PAS density was quantified with digital image analysis.ResultsThirty-four patients (49 %) presented with blurred vision. 18 (26 %) with a shadow in the visual field, 7 (10 %) with photopsia and/or floaters and 2 (3 %) with metamorphopsia. Nine patients (13 %) had no symptoms at all. Median follow-up was 16.7 years (SD 2.6). A shadow in the visual field, but no other symptom, was positively correlated with the presence of VM (φ 0.70, p<0.001) and greater PAS density (p<0.001). In multivariate regression, retinal detachment (RD), presence of VM and PAS density ≥ median were independent predictors of a shadow, but not tumor distance to the macula, tumor apical thickness, tumor diameter or ciliary body engagement. Presence of VM was associated with significantly shorter cumulative disease-specific survival (Wilcoxon p=0.04), but not PAS density ≥ median, presenting symptoms or RD (p>0.28).ConclusionTumors from uveal melanoma patients that report a visual field shadow are likely to display VM and greater PAS density, likely explaining the previously reported association between this symptom and poor prognosis.


Brachytherapy ◽  
2017 ◽  
Vol 16 (6) ◽  
pp. 1225-1231 ◽  
Author(s):  
Alexander J. Lin ◽  
Yuan J. Rao ◽  
Sahaja Acharya ◽  
Julie Schwarz ◽  
Prabakar Kumar Rao ◽  
...  

Brachytherapy ◽  
2013 ◽  
Vol 12 ◽  
pp. S19
Author(s):  
Shahed N. Badiyan ◽  
Rajesh C. Rao ◽  
Anthony J. Apicelli ◽  
Sahaja Acharya ◽  
Vivek Verma ◽  
...  

2020 ◽  
pp. bjophthalmol-2019-314802
Author(s):  
Rumana Hussain ◽  
Florian Moritz Heussen ◽  
Heinrich Heimann

IntroductionUveal melanoma is most commonly treated with radiotherapy, destroying the tumour cells with adequate safety margins and limiting collateral damage to surrounding structures to preserve maximal vision. We used optical coherence tomography (OCT) to study the effects of radiotherapy on the retina.MethodsPatients with posteriorly located choroidal melanoma treated with proton beam radiotherapy (PBR) and ruthenium-106 brachytherapy between January 2010 and June 2014 underwent spectral domain OCT.ResultsImages of 32 patients following ruthenium-106 brachytherapy and 44 patients following proton beam teletherapy were analysed. Following plaque brachytherapy, an early marked disruption of the outer retinal layers could be observed in 30 cases (94%) with retinal atrophy evident in 26 cases (81%). In contrast, the images from patients who underwent PBR showed subtle outer retinal layer change with 16 cases (36%) showing some inner-outer segment junction disruption by 6 months and 63%  by 24 months with minimal atrophy. In cases with tumours <2 mm from the fovea, the visual loss was significantly less at 6 and 12 months in the proton beam group.ConclusionIn comparison to ruthenium-106 plaque brachytherapy, PBR leads to more subtle and slower changes in the outer retinal layers enabling retention of visual function for longer. The difference in dosing regime and dose distribution across the tumour is likely to be causative for this structural differential.


Brachytherapy ◽  
2014 ◽  
Vol 13 (6) ◽  
pp. 584-590 ◽  
Author(s):  
Christopher A. Barker ◽  
Jasmine H. Francis ◽  
Gil'ad N. Cohen ◽  
Brian P. Marr ◽  
Suzanne L. Wolden ◽  
...  

2004 ◽  
Vol 138 (3) ◽  
pp. 518
Author(s):  
E.C. Sener ◽  
H. Kiratli ◽  
S. Gedik ◽  
A.S. Sanac

2011 ◽  
Vol 99 ◽  
pp. S354
Author(s):  
K. Leonard ◽  
N. Gagne ◽  
J. Mignano ◽  
J. Duker ◽  
E. Bannon ◽  
...  

2015 ◽  
Vol 93 (3) ◽  
pp. E77-E78
Author(s):  
P. Jiang ◽  
G. Kanzia ◽  
D. Neumann ◽  
J. Roider ◽  
J. Dunst

Sign in / Sign up

Export Citation Format

Share Document